Enwei Pharmaceutical Co., Ltd. (SHE:301331)

China flag China · Delayed Price · Currency is CNY
27.11
+0.14 (0.52%)
At close: Apr 30, 2026
6.86%
Market Cap 2.74B
Revenue (ttm) 879.60M
Net Income (ttm) 48.14M
Shares Out 101.08M
EPS (ttm) 0.46
PE Ratio 58.48
Forward PE n/a
Dividend 0.35 (1.30%)
Ex-Dividend Date Jan 8, 2026
Volume 1,325,252
Average Volume 1,180,792
Open 27.10
Previous Close 26.97
Day's Range 26.67 - 27.22
52-Week Range 24.10 - 39.66
Beta 0.65
RSI 54.11
Earnings Date Apr 27, 2026

About Enwei Pharmaceutical

Enwei Pharmaceutical Co., Ltd. engages in the development and sale of Chinese medicines in China. The company offers drugs in the areas of gynecology, pediatrics, and respiratory system fields. The company was founded in 2005 and is based in Chengdu, China. [Read more]

Sector Healthcare
Founded 2005
Employees 1,548
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301331
Full Company Profile

Financial Performance

In 2025, Enwei Pharmaceutical's revenue was 900.77 million, an increase of 10.91% compared to the previous year's 812.13 million. Earnings were 51.94 million, an increase of 38.53%.

Financial Statements

News

There is no news available yet.